Skip to Content

Entia Biosciences Inc ERGO

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ERGO is trading at a 38% discount.
Price
$0.00
Fair Value
$2.32
Uncertainty
Extreme
1-Star Price
$9.77
5-Star Price
$8.38
Economic Moat
Qkwmnm
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ERGO is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
$0.03 / $0.05
Market Cap
$3,366.09
Volume/Avg
8,749 / 6,373

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Entia Biosciences Inc operates as a biotechnology company, is engaged in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products, principally in the United States of America. It market nutraceutical products under the name GROH and SANO directly to the consumers online. It currently offers natural organic nutraceutical mushroom dietary supplement products, ImmuSANO, GlucoSANO, and GROH, which has been designed to nutritionally support hair follicles and nail beds. It derives its revenue from the sale of its GROH line and mushroom-based nutraceutical dietary supplement products and functional ingredients.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
7

Valuation

Metric
ERGO
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ERGO
Quick Ratio
0.04
Current Ratio
0.11
Interest Coverage
−15.71
Quick Ratio
ERGO

Profitability

Metric
ERGO
Return on Assets (Normalized)
−278.64%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
ERGO
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRHhp$550.2 Bil
VRTX
Vertex Pharmaceuticals IncKbqddsq$111.1 Bil
REGN
Regeneron Pharmaceuticals IncSxcnkx$107.7 Bil
MRNA
Moderna IncMthz$36.9 Bil
ARGX
argenx SE ADRRrt$24.2 Bil
BNTX
BioNTech SE ADRQpcrr$22.3 Bil
ALNY
Alnylam Pharmaceuticals IncSygwtt$19.9 Bil
BMRN
Biomarin Pharmaceutical IncRgrrln$17.2 Bil
RPRX
Royalty Pharma PLC Class AJnbrxlv$13.9 Bil
INCY
Incyte CorpSvxwbn$13.6 Bil

Sponsor Center